Monday, June 15, 2026

Hyosung Lands a Record $590M U.S. Grid Deal: 765 kV Transformers Powering the AI Data-Center Boom

Hyosung Heavy Industries secures a $590.25M contract for ultra-high-voltage transformers in the U.S., reinforcing its market leadership.

LS Electric Shares Top 200,000 KRW… Hit Record High on AI Data Center Supply

LS Electric's stock price surged past 200,000 KRW due to a major contract for AI power distribution panels with U.S. tech firms.

Kim Jong Un Inspects New Pyongyang Hospital, Calls Out Officials for Delays and Mismanagement

Kim Jong Un inspected the nearly finished Pyongyang General Hospital, criticizing officials for discipline violations and emphasizing health reform.

Tag: 2026

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Penetrium Bioscience Announces Finalization of New Clinical Strategy for Targeted Cancer Therapies

Penetrium Bioscience reveals new clinical strategy to combat drug resistance in cancer therapies at AACR 2026, launching Phase 2 trials.

Nesuparib: The Revolutionary Dual-Inhibitor for Pancreatic Cancer – Can It Outperform Existing Treatments?

Nesuparib shows promise in inhibiting pancreatic cancer metastasis, offering hope for patients regardless of BRCA mutation status.

Lunit’s AI-based bile duct cancer study selected for rapid oral presentation at U.S. oncology conference

Lunit will present five research abstracts at ASCO 2026, showcasing the expanding role of AI biomarkers in cancer treatment.

Verismo unveils preclinical data on improved antitumor efficacy and safety of blood cancer CAR-T at AACR

HLB Innovation's SynKIR-310 shows improved antitumor activity and safety in preclinical trials, achieving 100% survival in mice.

GC Biopharma Presents Aggregation Study of Alyglo IVIG… A New Benchmark for Safe Immunotherapy

GC Biopharma USA will present findings on IVIG formulations, highlighting Alyglo's lower protein aggregation and improved stability at NHIA 2026.

Next-Gen Cancer Drug Nesuparib: How It Outperforms Olaparib in SCLC and Pancreatic Cancer

Onconic Therapeutics will present Nesuparib research at AACR 2026, showcasing its potential for various cancers and overcoming PARP inhibitor limitations.

Neurophet Unveils AI-Powered Alzheimer’s Treatment Software at ITEM 2026 in Japan

Neurophet showcases AI-driven brain disease tech at ITEM 2026 in Japan, partnering with Hokuyaku Takeyama to expand market reach.

How Hanmi’s Dual Inhibitor HM97662 is Revolutionizing Cancer Treatment: Key Insights from AACR 2026

Hanmi Pharmaceutical to present nine groundbreaking cancer research studies at AACR 2026, showcasing innovative therapies and AI-driven analytics.

GI-101A: Breakthrough Immuno-Oncology Drug Set for ASCO 2026 Presentation

GI Innovation's GI-101A will be presented at ASCO 2026, highlighting its clinical potential and significance in oncology.

Alpha Tau Medical’s Alpha DaRT: A New Hope for Pancreatic Cancer Patients – What You Need to Know

Alpha Tau Medical will present clinical results of its DaRT technology for pancreatic cancer at DDW 2026, marking a significant milestone.

Unlocking Efficiency: How Capora’s AI-Driven TMS and WMS Transform Logistics in 2026

UMOS ONE unveils Capora, an AI-driven logistics service, at KOREA MAT 2026, enhancing efficiency in transportation and warehousing.

Classys Unveils Aggressive Growth Strategy at AAD 2026: What’s Next for the U.S. Market?

Classys reveals its growth strategy for the U.S. market at AAD 2026, showcasing innovative products and emphasizing clinical efficacy.

Wantech Targets U.S. Market Expansion at AAD 2026: Key Strategies Revealed

Wontech aims to expand in the U.S. by showcasing products at the AAD and hosting Wave Denver 2026 for healthcare partnerships.

Hanwha Vision’s Next-Gen AI Hybrid Security Solution BLAZE Unveiled at ISC WEST 2026

Hanwha Vision showcased its AI video surveillance solution BLAZE at ISC WEST 2026, highlighting innovative features for enhanced security.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.